Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Recombinant Tissue Plasminogen Activator (rt-PA)
100%
Thrombolysis
100%
Intraventricular Hemorrhage
100%
Brain Hemorrhage
100%
Clot Resolution
100%
Placebo
75%
Bleeding
37%
Intracerebral Hemorrhage
37%
Hemorrhage Volume
25%
Severity Factor
25%
Ventriculitis
25%
Placebo-controlled
12%
Phase I Trial
12%
Treatment Strategy
12%
Blood Pressure
12%
Safety Profile
12%
Demographic Characteristics
12%
Treatment Phase
12%
Safety Outcomes
12%
Clot
12%
Intracranial Pressure
12%
Respiratory System
12%
Adverse Events
12%
Beneficial Effects
12%
Treatment Group
12%
Statistical Significance
12%
Cerebral Perfusion Pressure
12%
Active Treatment
12%
Intraventricular
12%
Glasgow Coma Scale
12%
Bleeding Events
12%
Acceptable Safety
12%
Safety Factor
12%
Safety Events
12%
Device Closure
12%
Outcome Mortality
12%
System Events
12%
Clot Lysis
12%
External Ventricular Device
12%
Evenly Distributed
12%
Historical Control
12%
P 0.1
12%
Resolution Rate
12%
Medicine and Dentistry
Low Drug Dose
100%
Blood Clot Lysis
100%
Cerebral Hemorrhage
100%
Alteplase
100%
Placebo
87%
Infection
25%
Severity Factor
25%
Brain Ventriculitis
25%
Clinical Trial
12%
Blood Pressure
12%
Bleeding
12%
Cerebral Perfusion Pressure
12%
Respiratory System
12%
Intracranial Pressure
12%
Glasgow Coma Scale
12%
Treatment Group
12%
Active Treatment
12%
Adverse Event
12%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Hemorrhage
100%
Alteplase
100%
Low Drug Dose
100%
Placebo
87%
Infection
25%
Brain Ventriculitis
25%
Clinical Trial
12%
Bleeding
12%
Adverse Event
12%
Glasgow Coma Scale
12%
Treatment Group
12%
Neuroscience
Intraventricular Hemorrhage
100%
Alteplase
100%
Cerebral Hemorrhage
100%
Placebo
87%
Ventriculitis
25%
Cerebral Perfusion Pressure
12%
Glasgow Coma Scale
12%